COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Expanded Access for ACE-011

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03724227
Expanded Access Status : No longer available
First Posted : October 30, 2018
Last Update Posted : July 17, 2020
Information provided by (Responsible Party):

Tracking Information
First Submitted Date October 26, 2018
First Posted Date October 30, 2018
Last Update Posted Date July 17, 2020
Descriptive Information
Brief Title Expanded Access for ACE-011
Official Title Expanded Access for ACE-011
Brief Summary This is an expanded access program (EAP) for eligible participants designed to provide access to ACE-011.
Detailed Description Not Provided
Study Type Expanded Access
Expanded Access Type Individual Patients
Condition Myelodysplastic Syndrome
Intervention Drug: ACE-011
ACE-011 will be administered subcutaneous injection
Other Name: Sotatercept
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Expanded Access Status No longer available
Eligibility Criteria

Inclusion Criteria:


Exclusion Criteria:


Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
Administrative Information
NCT Number NCT03724227
Other Study ID Numbers ACE-011
Responsible Party Celgene
Study Sponsor Celgene
Collaborators Not Provided
Investigators Not Provided
PRS Account Celgene
Verification Date October 2019